Report: Colorectal cancer market in Asia-Pacific region set to reach $3 billion by 2020
The Colorectal Cancer (CRC) therapeutics market in Asia-Pacific (APAC) is set to increase in value, from $1.9 billion in 2013 to $2.9 billion by 2020, at a compound annual growth rate (CAGR) of 6.5%, says a new report.
This expansion, occurring across India, Australia, China and Japan, will be driven by the increasing incident population and higher uptake of branded drugs and targeted therapies, as patient access to these more expensive treatments improves, according to the latest report from business intelligence provider GBI Research.
The moderate uptake of late-stage pipeline products panitumumab (Amgen’s Vectibix) and Xilonix, a first-in-class True Human (IgG1k) antibody from XBiotech, following their expected approvals between 2016 and 2018, will also help boost the market, along with ramucirumab (Eli Lilly’s Cyramza), TAS-102, TS-1 and MelCancerVac from DanDrit Biotech.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze